Sorafenib effective in patients with non-small cell lung cancer, but low survival rates reported

Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory," according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine, held Jan. 8-11, 2012.

Patients with lung cancer and a KRAS mutation are believed to have a and may not benefit from treatment with epidermal growth factor receptor , according to study author Wouter W. Mellema, M.D., a doctoral candidate at VU University Medical Center in Amsterdam.

"There is a great need for targeted treatment options for patients with non-small cell lung cancer () with a KRAS mutation," he said.

In the phase 2, multicenter study conducted in the Netherlands, researchers assigned 57 patients with NSCLC and a KRAS mutation to 400 mg of sorafenib twice daily.

At six weeks, Mellema and colleagues reported a rate of no progression of 52.6 percent. Fifteen patients stopped treatment before six weeks — 10 of whom stopped due to clinical progression. Median progression-free survival was 2.3 months, and median overall survival was 5.3 months. The researchers reported that 14 patients are still alive.

"Sorafenib could be a useful drug in this patient population by inhibiting the growth-stimulating signal of the RAS protein," Mellema said. "However, although showed relevant activity, the outcome was unsatisfactory."

Mellema and his team had conducted a pilot study in 10 patients, which showed "very promising results. Unfortunately, the results of the phase 2 study were less optimistic. We expected that progression-free survival and overall survival would be better [in the phase 2 study]," Mellema said.

He suggested that the KRAS mutation causes early progression by stimulating cell growth through an alternative pathway. "Future studies currently in preparation in our group should focus on simultaneous inhibition of these pathways," he said.

add to favorites email to friend print save as pdf

Related Stories

Antifolates show promise against NSCLC subtype

Nov 14, 2011

Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer ...

Recommended for you

Study pinpoints microRNA tied to colon cancer tumor growth

2 hours ago

Researchers at the University of Minnesota have identified microRNAs that may cause colon polyps from turning cancerous. The finding could help physicians provide more specialized, and earlier, treatment before colon cancer ...

Obesity tied to higher cancer risk for CRC survivors

4 hours ago

(HealthDay)—Colorectal cancer (CRC) patients who are overweight or obese when diagnosed appear to face a slightly higher risk for developing a second weight-related cancer, according to research published ...

User comments